AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00189397
Drug: azathioprine and corticosteroids for Parthenium dermatitis
RxNorm normalized name: parthenium hysterophorus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02544061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous dose
Trial: NCT04405206
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cape 1000mg/m2
Trial: NCT02269046
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/d,p.o,12 weeks.
Trial: NCT00557973
Drug: XP19986 SR1, 10 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Trial: NCT00557973
Drug: XP19986 SR1, 20 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Trial: NCT00557973
Drug: XP19986 SR1, 30 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Trial: NCT00557973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
Trial: NCT02578771
Drug: ZuraPrep with 70% IPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically
Trial: NCT02578771
Drug: ZuraPrep without 70% IPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically. 0% IPA
Trial: NCT02578771
Drug: ChloraPrep CHG/IPA Teal Tint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically
Trial: NCT02047227
Drug: Pergoveris®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
Trial: NCT02047227
Drug: GONAL-f®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
Trial: NCT02047227
Drug: Recombinant human chorionic gonadotrophin (r-hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
Trial: NCT01977937
Drug: Simple Syrup
RxNorm normalized name: Simple syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04753476
Drug: Standard treatment of Covid-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol
Trial: NCT03004443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution will be administered intravenously over a 2 to 2.5 hour period.
Trial: NCT00828854
Drug: Aromatase Inhibitor (AI) Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
Trial: NCT00116428
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
Trial: NCT03550950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as IV infusion or SC injection.
Trial: NCT01525706
Drug: Ethanol and Paclitaxel Injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
Trial: NCT04253912
Drug: VBP-245
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Povidone-Iodine Gel
Trial: NCT02031211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
Trial: NCT04627337
Drug: Saccharomyces Boulardii 250 MG
RxNorm normalized name: Saccharomyces boulardii 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yeast in capsules
Trial: NCT00487682
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03316339
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid anesthesia
Trial: NCT00236782
Drug: norelgestromin + ethinyl estradiol; mercilon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03080194
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject in control group will be applied with oral antipsychotics or other conventional medication.
Trial: NCT00111189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 4 wk up to 24 mo
Trial: NCT01273103
Drug: 200mg [14C]- GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral suspension dose of \[14C\]- GSK2248761 200 mg
Trial: NCT03539003
Drug: propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
Trial: NCT02395783
Drug: Melatonin 10 µg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Trial: NCT00600626
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01683253
Drug: Levodopa/Carbidopa(200mg/50mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01683253
Drug: Dopaminergic Agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated for at least 6 months after diagnosis of Parkinson's Disease.
Trial: NCT02395783
Drug: Melatonin 20 µg
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Trial: NCT03029273
Drug: Cyclophosphamide and Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
Trial: NCT01928914
Drug: Placebo for moxifloxaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Trial: NCT00542516
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
Trial: NCT01577537
Drug: 1% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel, daily for 7 days
Trial: NCT01577537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel, daily for 7 days
Trial: NCT01162928
Drug: Nutriflex Omega special + Oxepa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-chamber-bag combined with enteral nutrition
Trial: NCT01162928
Drug: Nutriflex Lipid special + Pulmocare
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-chamber-bag combined with enteral nutrition
Trial: NCT01501383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01674283
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00052273
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02315326
Drug: HD- Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
Trial: NCT02431845
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
Trial: NCT00514293
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00754988
Drug: Placebo (matching sitagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of placebo (matching sitagliptin).
Trial: NCT00418782
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00418782
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00754988
Drug: Placebo (matching taspoglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
Trial: NCT04473846
Drug: PK general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
Trial: NCT04473846
Drug: PFK combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
Trial: NCT04143087
Drug: withdrawal TKIs or halve TKIs
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop TKIs or treated by half TKIs
Trial: NCT00223171
Drug: Androgen blockade + radiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen blockade + radiation therapy
Trial: NCT04416984
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for lymphodepletion
Trial: NCT00675259
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
Trial: NCT01652196
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
Trial: NCT01652196
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
Trial: NCT03396523
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo (oral)
Trial: NCT05737329
Drug: Transdermal estradiol gel 0.1% 1.5mg/ day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
Trial: NCT00064181
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00064181
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00064181
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00064181
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00064181
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01739361
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01739361
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01044251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab po bid for 10 days
Trial: NCT01462643
Drug: LAS41004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, topical ointment, 100 microgram per day
Trial: NCT00472446
Drug: placebo bilateral superficial cervical block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
Trial: NCT04183790
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration
Trial: NCT03664180
Drug: Unfractionated heparin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Trial: NCT00658320
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
Trial: NCT01830920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A normal saline solution identical in appearance to the active drug solution
Trial: NCT01532882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, PO, 1 per day during 28 days
Trial: NCT02585258
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule containing a tablet of 5 mg prednisolone/ day
Trial: NCT01169090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01987284
Drug: SER100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01987284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02959983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching eluxadoline oral tablets BID with food.
Trial: NCT00789802
Drug: transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
Trial: NCT00789802
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
Trial: NCT00789802
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
Trial: NCT02277223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.
Trial: NCT01689636
Drug: Tc 99m EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00774332
Drug: CODOX-M
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
Trial: NCT01313728
Drug: Dapsone plus Tretinoin Gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
Trial: NCT01313728
Drug: Tretinoin Gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
Trial: NCT00621959
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg (matching oral tablet)for 14 days
Trial: NCT00041288
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00041288
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03239158
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT02484690
Drug: Sham Procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
Trial: NCT01448031
Drug: Acetylsalicylzuur Apotex Cardio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses administered on Day 1 to 5
Trial: NCT03783091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV administration of saline
Trial: NCT00384891
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation with BCG (Bacillus Calmette-Guérin)
Trial: NCT00309738
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01847001
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.